Selection of FIH dose based on preclinical data and competitor’s clinical data (if available)
Optimization of clinical study design: duration, patient stratification, pre-treatment, etc.
Selection of RP2D based on in vitro and early clinical data
Optimization of dose and regimen for investigated therapy
Comparison of investigated therapy with competitors
Evaluation and optimization of combination therapies
Identification of biomarkers predicting response
Investigation of the mechanism of action
Identification of best-in-class or optimal PK/PD properties
current focus
Therapeutic areas:
Immunology
Oncology and immuno-oncology
Neurodegenerative diseases
Infectious diseases
Rare diseases
previous experience
Therapeutic areas:
Inflammatory disease
Autoimmune disease
Diabetes and obesity
Cardiovascular diseases
Infectious diseases
Metabolic diseases
Diseases associated with kidney dysfunction
Diseases associated with Ca/phosphate/ FGFs homeostasis
Pain
We use cookies (and other similar technologies) to collect data to improve your experience on our site.
By using our website, you agree to data collection as described in our website’s data collection policy.
